0001628280-23-033914.txt : 20231004
0001628280-23-033914.hdr.sgml : 20231004
20231004214024
ACCESSION NUMBER: 0001628280-23-033914
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231002
FILED AS OF DATE: 20231004
DATE AS OF CHANGE: 20231004
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: McAvoy David R.
CENTRAL INDEX KEY: 0001758842
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-21088
FILM NUMBER: 231309713
MAIL ADDRESS:
STREET 1: C/O ENDOCYTE, INC., 3000 KENT AVENUE
STREET 2: SUITE A1-100
CITY: WEST LAFAYETTE
STATE: IN
ZIP: 47906
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Fresh Tracks Therapeutics, Inc.
CENTRAL INDEX KEY: 0000819050
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 930948554
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 5777 CENTRAL AVENUE
STREET 2: SUITE 102
CITY: BOULDER
STATE: CO
ZIP: 80301
BUSINESS PHONE: (720) 505-4755
MAIL ADDRESS:
STREET 1: 5777 CENTRAL AVENUE
STREET 2: SUITE 102
CITY: BOULDER
STATE: CO
ZIP: 80301
FORMER COMPANY:
FORMER CONFORMED NAME: Brickell Biotech, Inc.
DATE OF NAME CHANGE: 20190830
FORMER COMPANY:
FORMER CONFORMED NAME: VICAL INC
DATE OF NAME CHANGE: 19940211
4
1
wk-form4_1696470013.xml
FORM 4
X0508
4
2023-10-02
1
0000819050
Fresh Tracks Therapeutics, Inc.
FRTX
0001758842
McAvoy David R.
C/O FRESH TRACKS THERAPEUTICS, INC.
2000 CENTRAL AVENUE, SUITE 100
BOULDER
CO
80301
0
1
0
0
Gen Counsel, CCO, & Secretary
0
Common Stock
2023-10-02
4
M
0
20000
A
23419
D
Common Stock
2023-10-02
4
F
0
7358
0.9798
D
16061
D
Common Stock
310
I
By spouse
Restricted Stock Units
2023-10-02
4
M
0
20000
0
D
Common Stock
20000
0
D
The restricted stock units were granted on January 24, 2023 and were subject to accelerated vesting as of the date of the reporting person's termination pursuant to his employment agreement with the issuer.
Each restricted stock unit converted into common stock on a one-for-one basis.
This balance includes 555 shares purchased under the Fresh Tracks Therapeutics, Inc. Employee Stock Purchase Plan that were not previously reported.
On July 5, 2022, the registrant effected a 1-for-45 reverse stock split ("Reverse Stock Split") of its common stock. The number of shares beneficially owned has been adjusted to give effect to the Reverse Stock Split.
Represents shares withheld by the issuer to satisfy tax withholding obligations upon the vesting of restricted stock units.
The restricted stock units vested in full on October 2, 2023.
/s/ Christine G. Long, Attorney-in-Fact for David R. McAvoy (power of attorney previously filed)
2023-10-04